Neo Candimyk (Itraconazole)

Itraconazole works by inhibiting the fungal enzyme lanosterol 14α‑demethylase, a cytochrome P450 isoform essential for converting lanosterol to ergosterol. Blocking this step prevents the synthesis of ergosterol, a key component of the fungal cell membrane, leading to increased membrane permeability, impaired growth and ultimately fungal cell death.

The dosage of Neo Candimyk is individualized by the prescribing clinician based on the specific infection, patient weight, age, renal and hepatic function, and potential drug interactions. Healthcare providers determine the appropriate strength, frequency and duration of therapy according to current clinical guidelines and the patient’s overall condition.

Neo Candimyk is classified as Pregnancy Category D, indicating evidence of fetal risk and it should be avoided during pregnancy unless the potential benefit justifies the risk. It is also not recommended for breastfeeding mothers because itraconazole can be excreted in breast milk and may affect the infant.

To order Neo Candimyk, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The most common alternative to itraconazole is fluconazole, another oral azole antifungal. Itraconazole has a broader spectrum, covering many moulds such as Aspergillus, whereas fluconazole is primarily effective against yeasts like Candida. Itraconazole also has stronger activity against dermatophytes and certain dimorphic fungi, but it may have more drug‑interaction potential due to CYP3A4 inhibition.

Neo Candimyk should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments. No special refrigeration is required for this oral formulation.

Neo Candimyk is taken orally, usually with food or a full glass of water to enhance absorption. The exact administration schedule—such as once daily or divided doses—depends on the infection being treated and the prescriber’s instructions. Patients should follow the dosing regimen precisely and complete the full course, even if symptoms improve early.

Serious risks include hepatotoxicity, which may present as jaundice, dark urine or elevated liver enzymes, and cardiac failure, especially in patients with pre‑existing heart disease. Rare but severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome can also occur. Patients should seek immediate medical attention if they notice signs of liver injury, worsening heart symptoms, or severe skin reactions.

Neo Candimyk is contraindicated in patients with known hypersensitivity to itraconazole or any component of the formulation, in pregnant women (Category D), and in individuals with severe congestive heart failure. Caution is also advised for patients with significant liver impairment, as the drug is metabolized hepatically. Clinicians should evaluate each patient’s medical history before initiating therapy.